3d rendered illustration of HIV virus in blood stream

HIV Program Webinar Series: Immunopathogenesis of HIV-Related Cardiovascular Diseases

1:00 - 2:00 p.m. ET


This NHLBI HIV/AIDS Program webinar features Matthew J. Feinstein, M.D., M.Sc., Associate Professor of Medicine (Cardiology), Preventive Medicine (Epidemiology), and Pathology, and Director of Student Research at the Northwestern University Feinberg School of Medicine (NUFSM). In this talk, Dr. Feinstein will first provide a brief overview of the changing scope and presentation of cardiovascular diseases (CVDs) among people with HIV (PWH). Next, he will discuss the immunopathogenesis of HIV-associated athero-thrombotic disease and heart failure, including known and unknown mechanisms, as well as the potential implications for diagnosis and therapy. Finally, he will explore practical interim approaches, given limited clinical data to guide decision-making, to preventing and treating CVDs in PWH.

Register in advance for this meeting:

After registering, you will receive a confirmation email containing information about joining the meeting. This event is free and open to the public.

About the NHLBI HIV/AIDS Program and Seminar Series

This online seminar is part of a series that aims to facilitate information-sharing and stimulate scientific exchange in HIV-focused heart, lung, blood, and sleep research. The series is supported by the NHLBI HIV/AIDS Program, which leads global research, training, and education programs on HIV-related heart, lung, blood, and sleep (HLBS) disorders, as well as blood-based therapies.

Select Speakers

Matthew J. Feinstein, M.D., M.Sc.
Associate Professor in the Departments of Medicine (Cardiovascular Diseases), Preventive Medicine (Epidemiology), and Pathology at the Northwestern University Feinberg School of Medicine (NUFSM)
Dr. Matthew Feinstein is a cardiologist and physician-scientist focusing on immune plasticity in CVDs, with particular interest in human models of chronic immune dysregulation, including HIV. His goal is to refine targets that reprogram immune responses to ultimately resolve pathologic inflammation.
Matthew J. Feinstein, M.D., M.Sc.